Podcast appearances and mentions of stefan james

Många förbättringar sker nu inom hjärtvården. Kunskapen ökar kring behandling av 80-plussare som får hjärtinfarkt. Insikter finns även om när blodtryckssänkande behandling kan tas. Effekter av hur semaglutide (ozempic) påverkar hjärtsvikt har kommit. Lyssna på alla avsnitt i Sveriges Radio Play. Nyligen avslutades den stora europeiska hjärtkonferensen, European Society of Cardiology ESC, i London med över 30 000 forskare och läkare inom hjärt-kärlsjukvård.Världunikt om behandling av äldres hjärtinfarktDär presenterades en världsunik studie, Senior-Rita. Den handlar om vilken behandling som kan ges till äldre hjärtinfarktpatienter, som inte minst gäller kvinnor. Den visade att kranskärlsröntgen och ballongvidgning inte förlänger livet, men minskar risken för nya hjärtinfarkter och nya sjukhusinläggningar, berättar Sofia Sederholm-Lawesson, kardiolog vid universitetssjukhuset i Linköping.Ta blodtryckssänkande piller när det är lättastEn annan studie om blodtryckssänkande behandling visar att det inte spelar någon roll om läkemedlet tas på kvällen eller på morgonen, bara att man kommer ihåg att ta den.Illamående och mjukare hjärta med OzempicDet hypade diabetesläkemedlet semaglutide, med bland annat Ozempic, visar sig ha effekt också på hjärtsvikt, enligt en ny metastudie, berättar Lars Lund, professor i kardiologi vid Karolinska universitetssjukhuset i Solna.Men eftersom läkemedlet kan göra att man ständigt är illamående behöver det ställas in tillsammans med läkare, konstaterar professor i kardiologi Stefan James vid Akademiska sjukhuset i Uppsala. Han påpekar att motion och rätt kost är ett sätt att förebygga problemen och som inte ger några biverkningar. ProgramledareAnnika Östmanannika.ostman@sverigesradio.se

New Year, same Podcast! We are back with our 83rd episode and we brought our brother Sy to help us review the crime thriller, “21 bridges!” Jason thinks the mantle of Black Panther and T'Challa as T'Challa Jr should be given to Stefan James. Ray and Michael luck up or get set up and we debate if we would leave with anything . Jazz makes the situation a reality for us. Could the criminals have gotten away if they didn't caught on the traffic camera ? The cops are messy trying to clean up their mess and keep it from coming out . We catch up on a few current events and of course we answer, WAS IT GOOD THOUGH?

You're in control right? You have a belief that you can control situations, control others, and have a well laid plan for your life -- does that resonate with you? If so and you are looking for ways to let go then this episode is for you. In today's episode, host Jason Ramsden challenges your illusion of control, shares 5 tips for helping let go of control, as well as a fatherhood story about stopping to pressure his son academically and how it saved their relationship.RATE & REVIEW THE SHOWReview us on Love the Podcast or Apple Podcasts -- reviews and ratings help others find us and we appreciate your support greatly.ENGAGE WITH THE SHOWSubscribe, Facebook, Twitter or LinkedInCONNECT WITH JAYEmail, LinkedIn, Instagram, TikTok, or TwitterRESOURCESArticles5 mindfulness techniques for letting go of control by Anisa Purbasari Horton (fastcompany.com)Letting Go of Control by Stefan James (medium.com)10 Ways to Let Go of the Need to Control by Lauren Stahl (huffpost.com)App LinksCalm App; Calm is the #1 app for sleep and meditation. Join the millions experiencing better sleep, lower stress, and less anxiety. (Apple, Android)Amazon Links**EP30: Metahuma: Unleashing Your Infinite Potential by Depak Chopra, MD.EP19: Chatter;The Voice in Our Head, Why It Matters, and How to Harness ItEP11: Give and Take by Adam GrantEP04: The 5 Second Rule: Transform your Life, Work, and Confidence with Everyday Courage by Mel RobbinsEP02: Find Your Why by Simon Sinek (

P.S. I made it my sole mission to give away for free what many other business coaches sell in courses and programs. And I'm not slowing down anytime soon. Check out the FREE SECTION of the website here and let's start building your empire starting RIGHT NOW.Other resources that you may be interested in:Need to find clarity on your coaching niche? Get your hands on the Ultimate Niche Guide so you can find your niche and start owning it in 30 minutes or less!With the right systems in place, generating red-hot leads and attracting more coaching clients is possible. To learn more, get instant access to the Online Coaching Business Crash Course HERE while it's still free!There's more value waiting for you inside the Coaches Corner podcast! Hang out with and learn from celebrity guests like Elena Cardone, Evan Carmichael, Stefan James, Ali Brown, and more!Lucas Rubix is the intense-looking bearded dude (don't worry… he's actually harmless) behind the Coaches Corner, a corner of the internet completely committed to helping passionate coaches like YOU build, launch and grow a passion-fuelled, freedom-filled, money-making online coaching businesses (as long as you're not afraid of some work).Having built multiple coaching businesses (both offline and online) in a wide variety of niches, his primary focus these days (when he's not interviewing top coaches, influencers, and celebrities on the Coaches Corner Podcast) is helping coaches create a business that predictably generates leads, attracts new clients and, most importantly, creates true freedom (for both COACH and CLIENT)Visit www.LucasRubix.com and get full access into the 6 Figure Coach Academy, listen to a few episodes of the Coaches corner podcast while you're at it and feel free to connect with him on Instagram @LucasRubixAnd if you're a passionate coach who's looking for a helping hand in building, launching and growing your coaching business (and attracting all the perfect clients you've ever imagined) learn about the three ways you can work together HERE and see how Lucas can help you build the coaching business of your dreams!

P.S. Make each hour you spend working on your coaching business count! The Online Coaching Business Crash Course will show you what systems you can leverage to set up your coaching business for success! Get instant access HERE while we're still giving it away for free!

Why do some people seem to get rich, while others stay where they are no matter how hard they try? In this video, Dan and his good friend and mentee, Stefan James explain how to get rich: 10 reasons why most people don't become wealthy.

Stefan was born in Jamaica, raised in South Florida, and even has Chinese roots. But when his family came to the ‘burbs - “FOR SALE" signs came up. The son of an entrepreneur, his fearlessness, and love of business soon had him booking gigs in ...a teen boy band? Growing up and rising through the corporate ranks - Stefan experienced unconscious bias - on BOTH sides of the table. As a parent, Stefan now prepares his children for their lives as black Americans. And if our country’s “melting pot” misses the point, perhaps chili is better?  = MENTIONS... FILM: Love Jones (1997) PEOPLE:  Dave Chapelle (comedian) - his  INTERVIEW: Maya Angelou “Iconoclast” interview by Dave Chapelle https://youtu.be/okc6COsgzoE VIDEO: Dave Chapelle’s Acceptance of the Mark Twain Award: https://youtu.be/aeYA72NLaDE

Färre söker vård för hjärtbesvär nu när coronapandemin pågår. När är det viktigt att faktiskt ringa ambulans? Att färre söker vård för hjärtbesvär nu betyder inte att färre är sjuka, utan att man undviker att komma till sjukhus. Samtidigt skjuts behandlingar upp av vissa allvarliga hjärtsjukdomar. Vilka blir pandemins effekter på den akuta hjärtvården? Siffror från registret Swedeheart visar att det framför allt är de äldre som tycks undvika att söka vård för hjärtbesvär. Men det kan straffa sig i längden, och vården har resurser att ta emot dem, menar Stefan James , hjärtläkare och kardiologiprofessor vid Uppsala Universitet. Sverige har under mer än 30 år haft en oerhört positiv trend med att minska antalet som dör pga hjärtinfarkt. Det har farmför allt handlat om ändrad livsstil, enligt Annika Rosengren, medicinprofessor vid Sahlgrenska Akademien i Göteborg. Programledare: Annika Östman annika.ostman@sverigesradio.se Producent: Camilla Widebeck camilla.widebeck@sverigesradio.se

#263: Life Mastery with Stefan James Love this interview and actually it is one of my Favorite I have ever recorded. He has helped so many people become entrepreneurs through his youtube channel Project Life Mastery.  His website is https://projectlifemastery.com/ https://www.youtube.com/channel/Project Life Mastery (READY FOR THE NEXT GEN OF MENTAL PERFORMANCE?) GOLD LEVEL The 1% Performer Application SUPER-CHARGE YOUR BRAIN, MONEY & BRAND. Rewire and Upgrade to New Levels of Genius In 12 Weeks... CLICK HERE >>  https://andymurphy.biz/connect/     SILVER LEVEL  Exclusive to 1 Per Month. (CONNECT WITH ANDY) https://mindsetbydesign.co/free-focus-session   BRONZE LEVEL: Facebook Incubator group(3000 others inside) https://www.facebook.com/groups/mbdacademy LOVE THIS SHOW??? Listen, Subscribe and Pls Write a Quick Review Itunes >>>https://goo.gl/3QfHqU Stitcher >>> https://goo.gl/Xkdzi8 google for all platforms   Who has Worked with Andy Privately? https://andymurphy.biz/clients/   Ask Me how to take your life and business to a dream level Andy@mindsetbydesign.co

In this podcast, Stefan James from Project Life Mastery talks about the mistakes he made when he got started with Internet marketing. Building an online business isn't easy. There are a lot of factors to think about and decisions to make. A lot of online businesses fail because people make poor decisions that hurt their potential for success. Having an online business can change your life if you build it the right way. Stefan James from Project Life Mastery wants to help you avoid the mistakes he made with Internet marketing so that you can set yourself up for entrepreneurial success from the onset. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

How would your life change if you owned a million dollar business? In this interview with Stefan James from Project Life Mastery we discuss the so-called "playbook" to grow an eCommerce business and give you the freedom to move forward. Stefan is also an internet entrepreneur millionaire who makes content that inspires and moves people to take action. We talk about the mindset you will never to cultivate in order to make mistakes, beat the competition, and grow your business in 2020.

This podcast is about my successes and achievements in 2019. Creating this podcast was a little strange because it was all about me! This is not something that I normally do!However, I realize that many people enjoy learning more about me as a person, how I do things and what makes me tick. This is probably the reason that reality TV has become so popular.So, in this podcast, I talk quite a lot about Self Help for Life and how it has grown massively in 2019.I also share the success that I'm having with my Hypnotherapy practice in Sydney. I now have over 500 client hours and that was a big achievement for me.I'll reveal the key influencers in my life and the people that I learn from. I'll talk about books that I've read, the courses I attended and a cool meditation gadget that I have been using.I've had a lot of fun in 2019 as well. I've travelled to Borneo, Malaysia, Singapore and Ko Samui (in Thailand). I talk about these trips and include some photos as well.Products and services mentioned in this podcastF:100 day challenge: https://selfhelpforlife.com/100daychallengeMarissa Peer Masterclass: https://selfhelpforlife.com/marisa-peer-masterclassHypnotherapy with me: https://selfhelpforlife.com/hypnotherapyMuse brain sensing meditation headband: https://selfhelpforlife.com/museSony MX1000 Mk3 Headphones: https://selfhelpforlife.com/sonymx1000mk3Most popular video blogs.How to Hypnotize yourself: https://selfhelpforlife.com/how-to-hypnotize-yourself/Reticular Activating System and Goals: https://selfhelpforlife.com/reticular-activating-system-and-goals/The Four Main Personality Types: https://selfhelpforlife.com/four-main-personality-types/The 7 Best Ways to Create a Burning Desire for Success: https://selfhelpforlife.com/burning-desire-for-success/The 12 Common Thinking Traps that Steal Your Happiness https://selfhelpforlife.com/common-thinking-traps-steal-happiness/How to Reprogram Your Subconscious Mind for Success: https://selfhelpforlife.com/reprogram-subconscious-mind/Top 3 Personal Development InfluencersAlex Haynes: https://youtube.com/modernhealthmonkMarissa Peer: https://selfhelpforlife.com/marisa-peer-masterclassStefan James: https://projectlifemastery.comMusic and Book linksMetric – Art of Doubt: https://selfhelpforlife.com/metric-artofdoubtKeane – Cause and Effect: https://selfhelpforlife.com/keane-causeandeffectMidge Ure: If I Was (Autobiography): https://selfhelpforlife.com/midgeure

Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley: And I'm Dr Greg Hundley, associate editor from the Pauley Heart Center in Richmond, Virginia, from VCU Health. Dr Carolyn Lam: You know what, Greg, I may have a hoarse voice today and I'm a little bit scratchy, but my goodness, I couldn't be more excited about this issue. It's the TCT issue. Dr Greg Hundley: Well Carolyn, I cannot wait to discuss with our listeners the feature article that compares Apixaban and a P2Y12 inhibitor without Aspirin, versus regimens with Aspirin in patients with AFib who have ACS, whether managed medically or with PCI, or also those undergoing elective PCI that experience regimens that include vitamin K antagonists, aspirin, or both, but more to come later. Carolyn, should I start with my first discussion article and we grab a cup of coffee? Dr Carolyn Lam: You bet, Greg. Dr Greg Hundley: So my first article is from Seung-Jung Park from the Asan Medical Center at the University of Ulsan College of Medicine. So Carolyn, here's our first quiz question. In terms of Ticagrelor, have studies been performed in those from Asia evaluating bleeding risk? Dr Carolyn Lam: You know, I have to admit, Greg, I'm not totally familiar with the literature, but I do know that it's a very important question for us practicing in Asia. We have a perception that the bleeding risk, especially intracranial bleeding, may be higher in Asians. Dr Greg Hundley: Absolutely. Well, in this multicenter trial, 800 Korean patients hospitalized for acute coronary syndromes with or without ST elevation, and intended for invasive management, were randomly assigned to receive in a one to one ratio, Ticagrelor with a 180 milligram loading dose, and then 90 milligrams twice daily, or Clopidogrel with a 600 milligram loading dose and 75 milligrams daily thereafter, and the primary safety outcome was clinically significant bleeding, which was a composite of major bleeding or minor bleeding according to the PLATO outcomes criteria at 12 months. Dr Carolyn Lam: Oh, so what did they find? Dr Greg Hundley: Well Carolyn, at 12 months, the incidence of clinically significant bleeding was higher in the Ticagrelor group than in the Clopidogrel group. So it was 11.7% versus 5.3, and that included major bleeding and fatal bleeding. They were also higher in the Ticagrelor group. The incidents of death from cardiovascular causes, myocardial infarction or stroke, was not significantly different between the Ticagrelor group and the Clopidogrel group, although there was a strong trend toward a higher incidence in the Ticagrelor group with a P value of 0.07. So consequently, Carolyn, these results identified safety concerns regarding bleeding complications of standard dose Ticagrelor in East Asian, Korean patients with acute coronary syndromes, and therefore large adequately powered randomized trials are needed to determine the optimal antithrombotic regimen in this patient population. Dr Carolyn Lam: Very important data for our patients, as is this next paper, which really examines the cost effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation. Now, these are results from the COAPT trial. As a reminder, the COAPT trial demonstrated that edge-to-edge transcatheter mitral valve repair using the MitraClip resulted in reduced mortality and heart failure hospitalizations and improved quality of life when compared with maximally tolerated guideline directed medical therapy in patients with heart failure and three to four plus secondary mitral regurgitation. In the current paper, first author Dr Baron from Lahey Hospital and Medical Center in Burlington, Massachusetts and St. Luke’s Mid America Heart Institute in Kansas City, as well as corresponding author Dr Cohen from University of Missouri, Kansas City, and their colleagues used data from the COAPT trial to perform a formal patient level economic analysis of the COAPT from the perspective of the US healthcare system, and they found that although the follow up costs were lower with the MitraClip compared with guideline directed medical therapy, and lower by more than $11,000 per patient. However, the cumulative two year costs remain higher by about $35,000 per patient with the transcatheter mitral valve repair, and this is all due to the upfront costs of the index procedure. Now when in trial survival, health, utilities, and costs were modeled over a lifetime horizon, transcatheter mitral valve repair was projected to increase life expectancy by 1.13 years, and quality adjusted life years, or QALYs, by 0.82 years at a cost of $45,648, yielding a lifetime incremental cost effectiveness ratio, or ICER, of $40,361 per life year gained, and $55,600 per QALY gained. Dr Greg Hundley: Very interesting. So how do we interpret these results for clinical practice? Dr Carolyn Lam: Ah, good question. So in order to place this in context, perhaps the most comparable case is the use of transcatheter aortic valve replacement, or TAVR. So based on the partner 1B trial, the ICER for TAVR, compared to medical therapy, was $61,889 per QALY gains. So this is very similar to what you just heard as the ICER for the transcatheter mitral valve repair. The cost effectiveness is also comparable for other commonly used treatments such as the implantable cardiac defibrillators for biventricular pacing, and was interestingly substantially more than the cost effectiveness of continuous flow LVADs, for example, and this is really discussed in a beautiful editorial by Dr Bonow, Mark, and O'Gara, and in this editorial, I think it's really important that they say the cost effectiveness projections really need to be placed in the context of continuing uncertainties regarding the interpretation of COAPT compared to that of the MITRA-FR trial, which reported no benefit of transcatheter mitral valve replacement compared to medical therapy, and so they warn that the current cost effectiveness analysis is not a carte blanche for interventional cardiologists to dramatically escalate their use of MitraClip procedure, and the data do support the thoughtful and deliberate use of this potentially life lengthening procedure in carefully selected patients and under very careful circumstances. You've got to read their editorial. Dr Greg Hundley: That sounds excellent, Carolyn. I really like that, putting that editorial that puts that data in perspective. Well, my next study really emanates from the ABSORB III trial, and it's from Dr Dean Kereiakes at the Christ Hospital Heart and Vascular Center. The manuscript addresses the long-term cardiovascular event rates among bioresorbable vascular scaffolds and drug eluting metallic stents. Dr Carolyn Lam: Greg, remind me, what were the results of the original ABSORB trial? Dr Greg Hundley: Right, Carolyn. So the ABSORB III trial demonstrated non-inferior rates of target lesion failure, cardiac death, target vessel myocardial infarction, or ischemia driven target lesion revascularization at one year with the bioresorbable vascular scaffolds compared with cobalt chromium everolimus-eluting stents, but between one year and three years, and therefore the cumulative to 3 year time point, the adverse event rates, particularly for target vessel myocardial infarction and scaffold thrombosis, were increased with this bioresorbable vascular scaffold. Dr Carolyn Lam: Ah, I see. Okay, so this current study evaluated the outcomes from three to five years beyond the implantation? Dr Greg Hundley: Exactly. So what this study did is they looked at an interval of time between three and five years out, and they found reductions in the relative hazards for the bioresorbable vascular scaffolds compared to the common coated stents, and that particularly occurred for target lesion failure, either cardiac death or target vessel MI or ischemia driven target revascularization when compared to the earlier zero to three year time period. So therefore Carolyn, the authors conclude that improved scaffold design and development techniques to mitigate that zero to three year bio resorbable vascular scaffold risk may enhance the late benefits that one sees in this three to five year time point, because of the complete bioresorption. Dr Carolyn Lam: So that's interesting Greg. Well, my next paper is kind of related. It is the first report of a randomized comparison between magnesium based bioresorbable scaffold and sirolimus-eluting stent in this clinical setting of STEMI with one year clinical and angiographic follow-up. So this study is from the Spanish group, Dr Sabaté and colleagues from the Interventional Cardiology Department and Cardiovascular Institute in Barcelona in Spain, and they found that at one year when compared to the sirolimus-eluting stent, the magnesium based bioresorbable scaffold demonstrated a higher capacity of vasal motor response to pharmacological agents, either endothelium, independent or dependent, at one year. However, the magnesium based bioresorbable scaffolds were also associated with a lower angiographic efficacy, a higher rate of target lesion revascularization, but without thrombotic safety concerns. Dr Greg Hundley: Wow, Carolyn, very interesting, and Dr Lorenz Räber and Yasushi Ueki wrote a very nice editorial on this whole topic of bioresorbable scaffolds, and they wonder about some of the unfulfilled prophecies. Great for our readers to put these two articles together. Now, how about in that mailbox, Carolyn? What have you got in there? Dr Carolyn Lam: First there's a research letter by Dr Kimura entitled Very Short Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in Patients with High Bleeding Risk, and that's insights from the STOPDAPT-2 trial. There's another research letter by Dr Lopes entitled The Hospitalization Among Patients with Atrial Fibrillation and a Recent Acute Coronary Syndrome, or PCI, Treated with Apixaban or Aspirin, and that's insights from the AUGUSTUS trial. A very interesting perspective piece by Dr Rob Califf entitled The Balanced Dysfunction in the Health Care Ecosystem Harms Patients, a really, really interesting read, especially those working in the U.S. healthcare system. An ECG challenge deals with fast and slow, long and shorter. I would love to give you a clue to what it is. It's got to do with the atrial ventricular nodes, but I'll let you take a look and test yourself. There’re highlights from the TCT by Drs Giustino, Leon, and Greg Stone, and finally there's Highlights from the Circulation Family of Journals by Sara O'Brien. Dr Greg Hundley: Very nice, Carolyn. Well, I've got just a couple reviews. Richard Whitlock in a primer provides a nice historical review of anticoagulation for mechanical valves. How do we get here in anticoagulating this particular patient population? Next, Dr Mark Brzezinski from Brigham Women's Hospital in the Harvard Medical School in an on my mind piece provides very elegant figures, beautiful figures, demonstrating inadequate angiogenesis within the fibrous cap of atherosclerotic plaques, and indicates this could be a source or thought of as a contributing factor toward plaque rupture. What an issue, and I can't wait to get onto that featured discussion. Dr Carolyn Lam: For our featured discussion today, it is a super-hot topic, and a question that comes up again and again in clinical practice. What is the right antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome, not just those treated with PCI, but also in those treated medically? Well guess what? We're going to have answers right here. I'm so pleased to have with us Dr Renato Lopes, who's a corresponding author from Duke Clinical Research Institute and our associate editor, Dr Stefan James from Uppsala University in Sweden. Wow. Very, very important question here. Renato, could you just start by outlining what is the AUGUSTUS trial? Dr Renato Lopes: The AUGUSTUS trial was basically one of the four trials trying to give an answer, or help answering about the antithrombotic therapy in patients with anti fibrillation and/or NACS and/or PCI. So in other words, this combination of patients undergoing PCI who require antiplatelet therapy and also patients with AFib who requires anticoagulation therapy, and in summary, what the AUGUSTUS trial did was randomize patients to Apixaban versus VKA, or aspirin placebo in a double blind fashion, and this was a two by two factorial design. So these were basically the two questions that we wanted to answer. Is Apixaban better than VKA, and is it safe to drop aspirin from this treatment strategy? Remembering that everybody received a P2Y12 inhibitor for at least eight months. So this was basically the design of the AUGUSTUS trial, trying to answer two questions in the same study, a two by two factorial design. Dr Greg Hundley: Very, very nice. And Renato, if I could, I mean I said it in the intro, but may I make sure I got it right. This is the only trial in the field that included patients with ACS that was managed medically. So that's a very important group of patients that we still don't know what the best regimen is, is that right? Dr Renato Lopes: That is correct. The other trials, the PIONEER, the RE-DUAL PCI and the VPCI, they only included patients undergoing PCI, and when we designed the trial, we thought that it would be important to also include the whole spectrum of ACS, including not only the PCI treated patients, but also the medically managed patients. Dr Greg Hundley: Well, super. So could you tell us now what were the results? Dr Renato Lopes: So first, in terms of the breakdown, we found that the breakdown of the PCI, ACS versus elective PCI, was really nice. We had about 60% of the trial being ACS patients, and about 39%-40% elective PCI, and then within the PCI, I think that our results pretty much reflect practice in a lot of parts of the world, which was about 39% medically managed and about 61% PCI treated patients. So to begin with, I think a very nice breakdown that gives us power to look at these three separate groups: ACS medically managed, ACS PCI treated, and also elective PCI, which allows us to understand the whole spectrum of coronary disease in patients also with AFib, and in summary, what we showed for the primary endpoint, which was clinical major or relevant non-major bleeding. Let's start with the Apixaban versus VKA comparison, and we show that Apixaban was safer than VKA in all three groups, in the ACS medically managed, in the PCI treated patients, and also in the elective PCI patients. There was no significant direction for those three subgroups, although it was borderline 0.052, just showing maybe a little bit less pronounced results in the elective PCI group, but nonetheless, I would say that in general, very consistent, and in terms of Aspirin for the primary endpoint, also no difference, no interaction among those three groups. In other words, as we increase substantially the risk of bleeding about two folds in all the three groups, ACS medically managed, PCI treated patients, and elective PCI patients, with about again, two fold increase in bleeding compared to placebo. If we go to ischemic events, again, that's our hospitalization and other that are ischemic events. In terms of Apixaban versus VKA, the results were very consistent with the overall trial among these three groups, and in terms of as ACS versus placebo, the results also for the ischemic events were also similar among the three groups. So again, reassuring that the main results of the trial were very consistent, regardless how patients were managed in terms of the ACS, medically or through PCI, and also included in the elect PCI group. Dr Carolyn Lam: Thank you for explaining that so well. Stephan, I would love for you to take us under the hood. What were the editors thinking when we saw this paper, why we're highlighting it now, and what do you think are the implications? Dr Stefan James: The AUGUSTUS trial was unique in many aspects. I think Renato highlighted a few of them. As he told, there have been several similar trials without the other DOAX, factor 10A inhibitors and the dabigatran, but the AUGUSTUS trial was larger. It includes, as you mentioned previously, patients with ACS and medical management, and it also was designed as a two by two factorial design. So it actually asks two different questions and made two different randomizations, both anticoagulation with the two different agents, Warfarin versus Apixaban, but also Aspirin versus placebo, and so it's possible from this trial to understand more of the different aspects of treating patients, these complex patients with atrial fibrillation, NACS or PCI, and gave the study group and us an opportunity to better understand all these complexities. So with that, I'd like to turn to Renato and try to, with that background that I just outlaid, and you just try to make us understand what are the clinical implications of these aspects of the trial and the treatment of Apixaban and Aspirin in these patients? Dr Renato Lopes: I think we were in the area that we desperately needed randomized data, because basically until five years ago, the standard of care of treating these patients was the classic triple therapy with Aspirin, Clopidogrel, and Warfarin, and this was based on no randomized trials and all observational data, and we know how problematic this is, and this field has evolved tremendously almost year after year since the PIONEER trial, since the RE-DUAL trial, and this year, we had AUGUSTUS and ENTRUST and I think now, as Mike Gibson used to say, that we have about 2.8 million different combination of antithrombotic strategies to treat these patients because we have different anticoagulants, different anti-platelets, different doses, different durations, different types of stents, which makes it really impossible for physicians or for any guidelines to contemplate all these options. So we really needed a few trials to at least try to give a few options that are evidence based and not just based on low quality of data, and I think now, if you look at the Augustus results, and the totality of the data from all these trials, which now is about almost 11,000 patients all together, actually almost 12,000 patients all together. I think that what we know today is that yes, the initial period in hospital for some time it's important to use Aspirin. I think this is an important point to highlight, Stephan, that Aspirin still needs to be used for the acute treatment, and I would say at least for the first few initial days while patients are still in the hospital, but then by the time of discharge, which sometimes might be five days, six days, seven days, I think that now the totality of data show that it's reasonable to drop Aspirin for most patients. So based on the AUGUSTUS results, what we show is that if you're going to use anticoagulation as Apixaban at the dose that is approved for stroke preventions in atrial fibrillation, combined with a P2Y12 inhibitor without Aspirin after the initial period, you have the best outcomes in terms of lower rates of bleeding, lower rates of hospitalizations, and we don't have to pay a cost in terms of ischemic events when we actually drop Aspirin and keep only the NOAC, in this case was Apixaban, plus a P2Y12 inhibitor, which most of the time was Clopidogrel, and here with AUGUSTUS, we basically show that this is true for patients with AFib and ACS, irrespective of the management with medical managing, with medical therapy, or with PCI. So I think that's an additional piece that that is true irrespective of how we're going to treat your ACS patient, or if the patient basically underwent elective PCI, and I think we learned today that the classic treatment therapy of VKA plus Aspirin plus P2Y12 inhibitor, so in other words, the triple classic triple therapy should generally be avoided. Dr Stefan James: Thank you Renato. I think that that was a very complete answer in this complex arena. I'd like just to mention that of course the AUGUSTUS, as well as the other trials, have their limitations, as all trials. Although it was large, it was powered for safety, for bleeding events, and it was not powered for ischemic events. Having said that, we still want to look at ischemic events and clinical outcomes, and to what degree do you think we can do that? What conclusions can we draw from an ischemic point of view because of the fact that the trial was underpowered for that interpretation? Dr Renato Lopes: That is a great question, Stephan, and in fact, if we look at events like stent thrombosis, they are very rare, and if you really want to attack a significant difference between Aspirin versus placebo in patients having stent thrombosis, we're really going to need a trial with about 30-40,000 people, which would be not feasible and not doable. So we need to be cautious when we analyze those events in the power trial for ischemic events. Nonetheless, there was a signal, if you look at all trials, and even in the meta-analysis that we published recently, that dropping Aspirin probably increased the risk of ischemic events, not in a statistically significant fashion, but nonetheless, this trend exists. The signal exists. So probably keeping Aspirin, add some protection for ischemic events, primarily stent thrombosis and myocardial infarction. The problem is a tradeoff. The problem is that the cost of adding aspirin is too high. So now the question to us, Stephan, is to look further into our data and in the combined data sets that we're trying to work with the other authors and try to identify, okay, Aspirin really increased the risk of bleeding, but is there a group of patients who might benefit from a little bit longer Aspirin? So that's the first question. Who are those patients? May be complex PCI, maybe bifurcation lesions, maybe multiple lesions, multiple stents, and second, if we decide to give Aspirin longer, how much longer should we give? Because again, the cost is very high in terms of bad bleeds. So we are trying now to identify what is the trade off, and who most benefit from keeping Aspirin longer, and for how long in a way the cost might be worth it to pay in exchange of potentially save some ischemic events? And with that, we can further refine the treatment that I think I highlighted before. For most patients, I think what I said before is probably reasonable. We can drop Aspirin by the time of discharge after a few days, but for a few patients, for some patients, it might be wise to keep Aspirin a little bit longer, and we are trying now to identify first, who those patients are and second, form how much longer should we keep Aspirin, since the 40,000 patient trial is very unlikely to happen. Dr Stefan James: I like his interpretation, Renato, although I wanted to highlight that there are limitations, I think this trial is extremely informant for clinicians. We learned a lot how to treat these very complex patients with complex treatments. Dr Carolyn Lam: No, I couldn't have agreed more. I mean quoting Mike Gibson, 2.8 million combinations. Well, at least we've talked about some of them here and had a very clear take home message, although with the caveats that we were discussing. Thank you so much, Stefan and Renato. This was really a great discussion, and thank you audience for joining us today. You've been listening to Circulation on the Run. Don't forget to tune in again next week. This program is copyright American Heart Association 2019.  

Enjoy this NEW interview with the POWER COUPLE from Project Life Mastery, Stefan and Tatiana James! Stephan takes us all the way back to his rough childhood and how it led to his discovery of self-development, and how he later applied it to dating, digital marketing and his overall life! Stefan's entrepreneurial journey is a story you won't want to miss and he also shares how he built his powerful YouTube channel "Project Life Mastery", which inspires millions of viewers daily throughout the world! The power couple also share how they met, their relationship rituals, and how they maintain a healthy and loving relationship while living the lives of their dreams!   Wanna Learn How Stefan & Tatiana have made millions online Register for the MASTERCLASS NOW! https://www.affiliatemarketingmastery.co/aff-masterclass-1?affiliate_id=2033204 (Hurry... Limited Spots Available) Follow STEFAN JAMES on Instagram: https://www.instagram.com/stefanjames23/ Subscribe to Project Life Mastery on YouTube: https://www.youtube.com/user/ProjectLifeMastery Follow TATIANA JAMES on Instagram: https://www.instagram.com/tatianajames26/   Join Omar x The Passionate Few's (FREE) “CEO VIP” LIST HERE FOR DAILY BUSINESS SECRETS FROM $10 BILLION DOLLARS WORTH OF ENTREPRENEUR: https://podcastmastery.org/optin-main __________ WANNA CONNECT W/ OMAR & ASK HIM ANY QUESTIONS Email OMAR ELATTAR Directly Here: Omar@OmarElattar.com Direct Message OMAR on Instagram Here: https://www.instagram.com/omar_therockstar/

Welcome to my third Quarterly Goals Report for 2019! Every month since 2012, I write a detailed report about my progress toward the goals and resolutions I publicly stated on my blog earlier in the year. I previously called this my Monthly Goals Report, but for 2019 I decided to try doing a Quarterly Goals Report instead. Since I started sharing my goals and progress in 2012, I have received such an amazing response from people all over the world. You've shared with me how I helped to inspire you by openly sharing my progress. And knowing you're reading this helps me hold myself accountable to the promises I've made to myself. This is my Quarterly Goals Report for Quarter 3 of 2019. It's my hope that you can take away something to inspire you in the pursuit of your own goals. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

Every month since 2012, I write a detailed report about my progress toward the goals and resolutions I publicly stated on my blog earlier in the year. I previously called this my Monthly Goals Report, but for 2019 I decided to try doing a Quarterly Goals Report instead. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

Chalene wanted to find someone to bring on Build Your Tribe who could really break down the essence of affiliate marketing, and she found... Stefan James! In this episode, Stefan and Chalene are going to give you all the ins and outs of affiliate marketing, and the different ways you can use it. Stefan has helped his own students build 5, 6, and even 7-figure businesses using affiliate marketing! If you want to make passive income or if you already do but want to learn how to make more, then this is your episode!! Get ready to take notes because Chalene and Stefan are going deep into affiliate marketing!   Find Stefan… Website Subscribe on YouTube Follow on IG and Twitter   Here’s The System I Use Every Day to be More Organized & Crazy Productive: www.smartlifepushjournal.com  Marketing Impact Academy Join our new awesome PodSquad on Facebook here: www.facebook.com/groups/ChalenePodSquad Get Episode Show Notes Here: www.chalenejohnson.com/podcast       Hey! Send me a tweet & tell me what you think about the show! (Use the Hashtag) #BuildYourTribe so I know you’re a homie! XOXO Chalene   Connect with me on your fav social platform. At the moment, mine is SnapChat: ChaleneOfficial      www.Facebook.com/Chalene www.Instagram.com/ChaleneJohnson www.Twitter.com/ChaleneJohnson

Welcome to my first Quarterly Goals Report for 2019! Every month since 2012, I write a detailed report about my progress toward the goals and resolutions I publicly stated on my blog earlier in the year. I previously called this my Monthly Goals Report, but for 2019 I decided to try doing a Quarterly Goals Report instead. Since I started sharing my goals and progress in 2012, I have received such an amazing response from people all over the world. You've shared with me how I helped to inspire you by openly sharing my progress. And knowing you're reading this helps me hold myself accountable to the promises I've made to myself. This is my Quarterly Goals Report for Quarter 1 of 2019. It's my hope that you can take away something to inspire you in the pursuit of your own goals. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

Stefan James is an internet entrepreneur, life and business coach, philanthropist, and world traveler with an obsession for mastering every area of his life, fulfilling his potential as a human being and making a difference in the lives of others. He reaches millions of people through his online videos, training programs and masterminds.   Our favourite conversations & takeaways from the W2S episode with Stefan James:   2 min:32 sec - Once I discovered the world of self-development, I realized that I can change my life, I can be whoever I want to be…   6 min :17 sec - Someone has an audience... What would be your advice on how to listen to them, on how to ask them like what it is what they want to get, to be able to create a product...   15 min: 58 sec - If you can go back 10 years and install 3 habits to your morning ritual ... What those 3 habits would be...   21 min: 43 sec - What is the vision for my business and my career?...   24 min: 49 sec - If someone wants to model Stefan James right now.. What are the things, the main things you will teach...   29 min: 21 sec - As an Entrepreneur, as an Artist... How will you go about finding your ideal partner...   39 min: 06 sec - The worst advice that ever got was to be yourself…be your best-self!…   45 min: 00 sec - What is the meaning of success to you?   48 min: 26 sec - I think Entrepreneurs they have to work smarter not just harder...   49 min: 16 sec -  What would you write down in a piece of paper if you have to leave on that day and hand it? And what would be your Words 2 Success?   3 top recommended books read by Stefan James in the past year:   The 100: A Ranking Of The Most Influential Persons In History 50 Psychology Classics Clockwork: Design Your Business to Run Itself   Additional information about Stefan James: Website: https://projectlifemastery.com/ (https://projectlifemastery.com/) Social Media: https://www.facebook.com/projectlifemastery (Facebook) https://www.instagram.com/stefanjames23/ (Instagram) https://twitter.com/prolifemastery (Twitter) https://www.snapchat.com/add/stefanjames1 (Snapchat) https://www.youtube.com/channel/UCKkg7omDlPvUPxLY-dho8Pg?sub_confirmation=1 (Youtube) https://www.periscope.tv/projectlifemastery (Periscope) https://www.pinterest.ca/prolifemastery/ (Pinterest) https://www.linkedin.com/in/stefanjames23/ (Linkedin) https://itunes.apple.com/us/podcast/project-life-mastery-podcast/id601690632 (Itunes - Podcast) https://www.stitcher.com/podcast/project-life-mastery-podcast-making-money-online-motivation (Podcast - Stitcher)   Congratulations to Stefan James for being featured in "https://www.entrepreneur.com/article/325807 (Entrepreneur.com)" in January 10th, 2019

HUGE ANNOUNCEMENT: My friends James Swanwick creator of The 30 Day No Alcohol Challenge are official sponsors of the SDL Podcast! http://30daynoalcoholchallenge.com/quinton And to celebrate I'm sharing a special interview with my good friend Stefan James (founder of Project Life Mastery) describe how this incredible program has changed his, and 1000's of others lives who took this simple 30 day challenge to either stop, or simply cut back in drinking. You will easily save more than the cost of this program buy all the money you will save by not drinking, and this is what motivated me to stop drinking and I have been 100% sober for over 2 years now! Enroll today, your liver and bank account will thank you and I will give you a free 1 on 1 coaching call and will mentor you throughout your 30 days when you get started today through my link here http://30daynoalcoholchallenge.com/quinton --- Send in a voice message: https://anchor.fm/self-developed-life/message

Dr Carolyn Lam:                Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. What are the long-term effects of oxygen therapy in patients with suspected acute myocardial infarction? Well, to find out, stay tuned for our discussion of our feature paper this week, coming right up after these summaries.                                                 The first two original papers demonstrate that, similar to neonatal mice, one day old and two-day old neonatal pigs are capable of mounting a cardiac regenerative response following myocardial infarction, which is characterized by restoration of contractile function, cardiomyocyte replenishment, and minimal fibrosis. Now, interestingly, this regenerative capacity is lost after the first two days of life.                                                 The first paper is from co-corresponding authors, Drs Yeh and Cook from National Heart Research Institute of Singapore and National Heart Center, Singapore, and the second from co-corresponding, authors Drs Zhang and Zhu from the University of Alabama at Birmingham.                                                 These authors report collectively that proliferation of preexisting cardiomyocytes appear to be the primary source of cardiomyocyte replenishment in neonatal pigs with markers of cardiomyocyte mitosis, sarcomere disassembly, and cytokinesis elevated following injury in the one day and two-day old hearts, but not at later time points.                                                 Furthermore, cardiomyocyte DNA synthesis was increased following neonatal pig myocardial infarction. Cardiomyocyte proliferation significantly decreased after this two-day window, which was associated with a marked reduction in telomerase activity.                                                 Heart failure with preserved ejection fraction may look different in the young compared to that in the elderly. First author, Dr Jasper Tromp, corresponding author, myself, Carolyn Lam from the National Heart Center, Singapore and Duke National University of Singapore, and our colleagues from the Asian Heart Failure Registry studied more than 1,200 patients with HEF PEF from 11 Asian regions and found that 37% of our Asian HEF PEF population was under 65 years of age. Younger age was associated with male preponderance, a higher prevalence of obesity, and less renal impairment, atrial fibrillation, and hypertension. Left ventricular filling pressures and the prevalence of left ventricular hypertrophy was similar in the very young of less than 55 years and elderly HEF PEF of more than 75 years of age.                                                 Compared to age matched controls from the community without heart failure, the very young HEF PEF patients had a three-fold higher death rate and twice the prevalence of left ventricular hypertrophy. Thus, young and very young patients with HEF PEF display similar adverse cardiac remodeling as their older counterparts, but very poor outcomes compared to controls without heart failure.                                                 Obesity may be a major driver of HEF PEF in a high proportion of HEF PEF in the young and very young.                                                 How important is hospitalization for heart failure as a complication of diabetes? In the next paper from first and corresponding author, Dr McAllister from University of Glasgow, the authors examined the incidents and case fatality of heart failure hospitalizations in the entire population age 30 years and older resident in Scotland during 2004 to 2013.                                                 Over the 10-year period of study, among 3.25 million people, the coot incidence rates of heart failure hospitalization were 2.4 per thousand-person years for those without diabetes, 12.4 for those with type two diabetes, and 5.6 for those with type one diabetes. Heart failure incidents had fallen over time for people with and without diabetes, but remained around two times higher in people with diabetes than those without diabetes. Heart failure case fatality was higher in people with type one diabetes. Duration of diabetes and glycated hemoglobin was associated with increased risk of heart failure in type one and type two diabetes. Thus, clinicians should be aware of the importance of heart failure and diabetes, especially in type one diabetes where this is under appreciated.                                                 What are epigenetic mechanisms contributing to ischemia reperfusion injury? Co-first authors Dr Yu, Yang, and Zhang, co-corresponding authors, Dr Xu from Nanjing Medical University, Dr Sun from Fudan University, and Dr Ge from Fudan University, and their colleagues evaluated the potential role of megakaryocytic leukemia one, or MKL 1, as a bridge linking epigenetic activation of NAD pH oxidases, or NOX, to reactive oxygen species production and cardiac ischemia reperfusion injury in mice. They found that genetic deletion of pharmaceutical inhibition of MKL 1 attenuated cardiac ischemia reperfusion injury in mice. MKL 1 levels were elevated in macrophages, but not in cardiomyocytes in vivo, following cardiac ischemia reperfusion injury.                                                 MKL 1 recruited the histone acetyltransferase, MOF, to activate NOX transcription in macrophages. Pharmaceutical inhibition of MOF attenuated cardiac ischemia reperfusion injury in mice, and pharmaceutical inhibition of NOX one or four attenuated cardiac ischemia reperfusion injury as well.                                                 These findings provide a novel link between MKL 1-mediated epigenetic regulation of gene expression in macrophages and ischemic heart disease. This opens the door to small molecule compounds targeting the MKL 1 MOF NOX access as a novel therapeutic strategy against ischemic heart disease.                                                 Is the time from last hospitalization for heart failure to placement of a primary prevention ICD associated with patient outcomes? First and corresponding author Dr Ambrosy from the Permanente Medical Group in San Francisco performed a post hoc analysis of Medicare beneficiaries enrolled in the national Cardiovascular Data Registries implantable cardioverter defibrillator, or ICD registry, all with a known diagnosis of heart failure and an ejection fraction of less than 35%, undergoing a new ICD placement for primary prevention.                                                 They found that older patients, currently or recently hospitalized for heart failure, undergoing initial ICD placement for primary prevention, experienced a higher rate of periprocedural complications and were at increased risk of death compared to those receiving an ICD without recent heart failure hospitalization. Additional prospective real world pragmatic comparative effectiveness studies should be conducted to define the optimal timing of ICD placement.                                                 The final original paper presents result of the VERDICT trial, a large scale randomized controlled trial evaluating the value of very early invasive strategy conducted within 12 hours of diagnosis on long term clinical outcomes in patients with non-SD elevation acute coronary syndrome. First and corresponding author Dr Kofoed from University of Copenhagen and colleagues studied 2,147 patients who were randomized and found that an invasive strategy performed within 4.7 hours after diagnosis was not associated with improved outcomes, compared to an invasive strategy conducted within two to three days.                                                 However, in the pre-specified subgroup of patients with a GRACE risk score of more than 140, a very early invasive treatment strategy did appear to improve outcomes, compared to a standard invasive treatment strategy. And that wraps it up for our summaries. Now, for our feature discussion.                                                 For our feature discussion today, we are talking about oxygen therapy for patients with suspected acute myocardial infarction. Something that seems so benign, something we've taken for granted, and yet now we now question since the Detox AMI trial. Well, for today's feature paper, we have a follow-up of this trial, and I'm so pleased to have actually our associate editor, but also author of this paper, Dr Stefan James from Uppsala Clinical Research Center, and the guest editor for this paper, Dr David Morrow, who's from Brigham Women's Hospital and Harvard Medical School. So, thank you both for being here.                                                 Stefan, could I just ask you to start by taking us back. How was Detox AMI first conceived? What made you even question oxygen therapy? And then, perhaps then, tell us about what this new paper adds. Dr Stefan James:              I think that's so interesting because I think we all learned in medical school that for myocardial infarction, you should always deliver oxygen. That's sort of the first choice. And the other sort of first choice that we learned was morphine. Some of the other important things that we learned was to give not only oxygen but morphine, and nitroglycerin, and perhaps aspirin. And by those four, only aspirin is really the agent that has been proven beneficial to patients.                                                 But we thought for many years actually about this oxygen hypothesis, or we were interested in trying to understand, is it really helpful to give patients oxygen? Or are we in fact harming patients? Because there is, as you may know, there is a metanalysis performed long ago with small trials on the fibrinolysis era that showed actually a threefold increased risk of dying in those patients who had received oxygen in randomized various small trials, and their animal experience actually suggesting that oxygen is also hazardous. You don't think about that so often, but it's really an agent that constricts arteries, and so as the arteries close by a clot in myocardial infarction, there is no way the oxygen that you breathe in your nose can reach the suffering myocardium. It actually contracts the arteries, and may make the infarct larger than it would be otherwise. Dr Carolyn Lam:                I love that explanation. Alright, so what did you find in the current analysis of longer term results? Dr Stefan James:              So, we performed this, the main oxygen trial that we call Detox. We built it upon our national registries, and so we decided to include not only MI patients, but patients who were suspected of MI, in order to be able to enroll patients before the diagnosis was clear. We didn't want to wait for troponins, so we enrolled patients in the ambulances, in the emergency departments, in the cath labs, or in the wards, patients who had suspected myocardial infarction.                                                 Most of them, eventually, did have myocardial infarction, but a proportion did not have myocardial infarction. They had other diseases that resembles MI and have breathing problems. And we selected the cut point of 90%. We said if they are below 90%, they're hypoxic, and it would be unethical to withdraw oxygen, if you were hypoxic. So, we sort of arbitrarily selected the cut point of 90%. And then, we randomized patients to receive oxygen or do not receive oxygen.                                                 We considered to do double blind, but in order to do a double blind, you need to provide air on a mask. And air is not available in ambulances or in the emergency department. We cannot put a mask without anything in it because then it will feel more difficult to breathe. So, we had actually oxygen versus nothing, and we enrolled all patients coming to the cath labs, and emergency departments, and ambulances in Sweden. And thanks to the infrastructure that we have built on the national registries, we were able to enroll these to conduct this large trial, larger than any other trial, 6,600 patients.                                                 In the main study, we found no benefit, and fortunately, no harm of providing oxygen for our primary end point, which was all caused death. But we realized that we were little bit underpowered actually to really clearly rule out that there was any benefit on the primary endpoints. And so, we said, we probably need a longer follow-up, and we probably also need other important measures such as heart failure. Because we thought that oxygen may, if it works, it may reduce the infarct size and may result in a lower risk of heart failure in the long-term. We don't believe that we will reduce the risk of re-MI because we're not interfering with atherosclerosis or plaque ruptures, but we may interfere with the development of heart failure.                                                 So, in this particular paper, we said, longer follow up in order for patients to possibly develop heart failure and increase their risk of heart failure hospitalizations. So, in this paper, we used as a primary endpoint of this analysis, death or hospitalization for heart failure, post MI. And with this way of calculating events, we are more sure that we are not underpowered for this evaluation. Dr Carolyn Lam:                Right. And the results? Dr Stefan James:              The results were completely neutral. There was no benefit at all in any sub group. It doesn't matter if you were ST elevation MI, or no ST elevation MI, or no MI, or high risk prior MI, prior heart failure, respiratory disease, there is no benefits and no harm, which is good. And those results are supported by our findings on troponin levels. So, we checked troponins repeatedly. I shouldn't say top troponin, but the highest measured, we did not find any difference between the two groups in Troponin elevations. And we did not find any difference in LVEF and in Echo performed during the initial hospitalization.                                                 So, I think both of those results support the primary endpoint of death and repeat hospitalization for heart failure. Dr Carolyn Lam:                So David, you've thought a lot about this, and also framed it so nicely when we were just talking a little bit earlier. What do you think is the real significance of this paper on so many levels? Dr David Morrow:            Yeah, I think there are many levels. I think it's such important work because it takes something that we are still doing in many hospitals every day for patients and is difficult to study because it's become part of standard of care, as Dr James pointed out, and so the authors are to be congratulated for being able to study this intervention. And I think in additionally because it is a therapy that's not associated with high cost, has been part of our care for so long, it's not one where there is the support for a large type of randomized trials. So, the ability to perform this with relatively low costs by nesting it in a registry is important, not only for this particular test, but also as a model for future research of so many interventions that we make right now where they started in a time where our threshold for a need for data was much less. Dr Carolyn Lam:                Yeah. Indeed. That's wonderfully put. I am also really struck. It's the importance of the message, but also especially about how you do a pragmatic registry-based randomized trial. The ability of Sweden to do this, it's just rock the world, right? Because we really need solutions like that for our clinical trial world, which has to be sustainable somehow. Could you maybe take us behind the scenes a little bit? I mean you did already in your description. I didn't realize there were so many considerations when you're planning this, but how easy or difficult is it to do a trial like this? Dr Stefan James:              We call the entity RRCT. We call it registry based randomized trial, but being aware that there is no strict definition of what is a registry based randomized trial. So, sometimes for some simple interventions like strategies, we can use only the registry for collection of baseline variables, procedure variables, and also outcomes. The registry can really do everything. The only thing we need to add is a randomization, so then we just program into the registry, which is used live in front of the patients.                                                 So, when I enter a patient in the registry, the personal identification number collects me to the population registry that supports directly back to me name and gender of the patient, and then I enter all the baseline characteristics anyway in the registry. And then, there is a question that comes up that screens my patients. So, the system proposes to me to randomize patients who are eligible because I programmed the inclusion/exclusion criteria. So, it proposes to every doctor in the country, this is a patient that is eligible potentially for this trial and just click randomize, and that's the trial. Everything is completed by that. No extra tests, no visits, no follow up, no telephone calls.                                                 That's the basic, very simple format that can only be used for a strategy, like a device or a strategy. But many of the questions we have in medicine are really regarding strategies. How long should you treat? How often do you need to come back? Sort of strategies. Then, when we've tried to expand this to pharmaceutical agents, and oxygen was the first pharmaceutical agent that we wanted to try. You may not consider oxygen as a pharmaceutical agent, but it is in fact. But it's not manufactured by any companies, and we are still, in this trial, wanted to keep all-cause mortality as the primary end point because that's very reliable. That's indisputable, and in our country it's absolutely 100% correct. If they registered dead, they are dead. There's no question.                                                 The next level we did in the validate was a true pharmaceutical agent manufactured by a company, [byobatterin seprin 00:18:31]. A little bit more complex because you need to be careful about making sure that the patients are receiving the pharmaceutical agent in the right manner, in the right time point. We need to be a little bit careful about collection of side effects, and complications, and so on, but it also worked very well in that trial. If they validated, we did actually adjudicate events because in the primary end point we had it where it was more complex primary endpoint, including myocardial infarction. If you include myocardial infarction or bleeding events, that needs to be defined in a certain way according to protocol. You need to adjudicate. If you really need to rely on the outcome assessment.                                                 We're not trying to take this type of study to the next level, to use it for typical oral pharmaceutical agents. Our largest trial now running is the spirit HFPF lactone versus no treatment in patients with HFPF. And again, this is a pharmaceutical agent that is a very inexpensive. There's no company that would sponsor such a trial, but we think it's a really important question. There's so many patients that suffer from HFPF, and in order to do that trial, it has to be simple and inexpensive.                                                 So, that's running. We hope to be successful. There are, of course, many challenges. Like any other trial, it's difficult to write a protocol. You have to be very dedicated and detailed for any trial. So backstage, this is not easier than any other trial, but for the investigator, it is much easier. That's the reason we have succeeded to reach out to every hospital in the country, and every physician seeing these patients are investigators. And many of them have never done any trials before. They have no experience with research, but still they should be able to randomize and do the trials because it seems to be so easy for them and for the patients. That's the whole idea. Dr Carolyn Lam:                Yeah. I'm just enamored by the whole concept, and of course, a lot of people I think are wishing that we could institute that in all countries as well. Trust me, a lot of conversation has occurred about that in Singapore, for example, where population based capture is possible. But, as you said, it's not that easy. It's got to be well thought out. Protocols still have to well thought out. Investigators still need to be trained, and so on. Dr Stefan James:              We want the investigators to feel that it's easy, that it's attractive to participate. Not for money, just because it's so easy and so interesting to be part of such an experiment. Dr David Morrow:            I think testing some of those therapies that are commonplace that they're used to, and our nature of practice is this is the perfect type of setting than more complicated interventions where you may need to train the investigators more in order how to implement to them, and apply the therapy correctly. That's the new trend, is ... I think the key issue is that in order to reliably test things where mortality is not the acceptable outcome that you could power adequately for, it's really the endpoint collection in the safety collection, and because of the robust medical record systems you have, you're able to do that. And we're so far from being able to do that reliably in the United States right now that it's not possible to do that. Unless we have specific well-constructed registries, which we do in some areas. I think we're learning, and hopefully we'll get there, but we're far behind [crosstalk 00:21:55]. Dr Stefan James:              [crosstalk 00:21:55] Yeah, but even- Dr David Morrow:            [crosstalk 00:21:57] Nationals- Dr Stefan James:              Even if you're not able to do a registry based, I think we all should consider in all trials to do it as easy as possible and really try to ask ourselves, what is the most important reason we're doing this trial? Sometimes we need to collect a lot of extra information because we need to understand the mechanisms or the side effects. If that's the case, I don't think at this trial methodology is not suitable. You shouldn't perform it that way. It needs to be the more traditional, more conservative, more expensive and burdensome way, but for many therapies, a more simple approach, more pragmatic approach is preferable. Dr Carolyn Lam:                Well, thanks again for diving into that because it gives us a real, to me at least, even greater appreciation for this paper when you understand the amount of work that's gone into it. But may I just end by saying, what do you think is the take home message for clinicians now? David, for example, you started by saying everyone's still doing it? I fully agree. Dr David Morrow:            Yeah. I think it's a very simple message, and that we know that oxygen is not effective in patients who have an oxygen saturation above 90%. And there's really no rationale to use it. Dr Carolyn Lam:                Perfect. Has this been put in practice in Sweden already? Dr Stefan James:              It has been. One of the virtues of running these registries is that we can also check the adherence to the results, so we can check that this is not used anymore. Dr David Morrow:            And since the investigators are your entire country, they all learned actually from participation in these trials. Dr Stefan James:              Exactly. Exactly. Dr David Morrow:            There's more of an investment in it already. Dr Carolyn Lam:                That's amazing. So, thank you again for sharing. Thank you for publishing this in circulation and for helping us to do that.                                                 You've been listening to Circulation on the Run. Don't forget to tune in again next week.                                                 This program is copyright the American Heart Association in 2018.  

There are many ways to make money online. The question is, which ways are the best? In this episode, my good friend and multi-millionaire, Stefan James, and I reveal 3 of the 7 best ways to make money online. Ready to unlock life-long financial confidence and become unstoppable? Pre Order Unlock it Here http://www.unlockitbook.com/ Join The Next Free Masterclass By Dan https://www.highticketcloser.com/masterclass Show notes and free resources https://danlokshow.com/

There are many ways to make money online. The question is, which ways are the best? In this episode, my good friend and multi-millionaire, Stefan James, and I reveal 3 of the 7 best ways to make money online. Ready to unlock life-long financial confidence and become unstoppable? Pre Order Unlock it Here http://www.unlockitbook.com/ Join […]

In this episode, Stefan James, Founder of Project Life Mastery, talks about how to master every area of your life.  Go to https://projectlifemastery.com/ to find out more. For more instant access to future episodes, subscribe to the podcast for free from your mobile device, laptop, or desktop computer.

Hey guys! Today I'm bringing you an exclusive interview with Stefan James from Project Life Mastery, one of my main influences for entrepreneurship and online business. We'll delve into his story, his evolution in online business and many other interesting tidbits. Make sure you don't miss this one!

Two weeks ago we dove into the topic of marketing and branding on YouTube for the first time with Dan Lok. Well today we’re back for part 2 with another entrepreneur who’s killing it on YouTube, Stefan James. Over the past five years, Stefan has built his channel up to 600,000 subscribers, and the results that investment has produced for his business has been life-changing. In fact, he gets over 1,000 to 2,000 new email subscribers every single day for free, just from that traffic produced by his videos. So today we’re going to dive into the details… How does he create his videos? What equipment does he use? Who does the editing? What does he do to prepare for each video? How does it optimize the headline to get the most amount of search traffic? And how does he turn these viewers, into paying customers. Today’s episode is packed with incredibly valuable insights and resources that will bring you up to speed on what you need to do to start building your YouTube channel today. If you’re not a Member of SelfMadeMan yet, you are missing out. We’ve just launched the private Facebook community for Members where myself, and our podcast experts are jumping to into the group live, to answer your biggest questions. And this is in addition to all of the incredible classes you’ll also have access to on the platform the moment you become a member. Head to SelfMadeMan.com now, and join us. Resources: ProjectLifeMastery.com Project Life Mastery on YouTube TubeBuddy Music: Music by: 3rd Prototype Song: I Know Licensed under a Creative Commons License

I’ve known Dan Lok for over ten years. We both got our start as online entrepreneurs around the same time, and we both did well, but then it felt like he disappeared for a while… I’d see his name pop up every now and then, but I really didn’t know what he was up to. I didn’t see him at any events, and then two years ago… BOOM… Dan is everywhere. He’s giving TED talks, his ads are all over the internet, and he’s suddenly become one of the most prominent figures in the entrepreneur space. So I had to find out what had changed… Where did this new Dan Lok come from, and how was he doing it. Well it turns out that the foundation to this new level in his career, was his YouTube Channel. Three years ago, Dan started uploading videos to his YouTube channel on a consistent basis. Growth was slow at first… it took him about two years to hit 100,000 subscribers on his channel. But then it started to go exponential, and within 6 months he hit 500,000 subscribers. Today he’s approaching 800,000 and will likely hit 1,000,000 within the next 3-4 months. And he’s not the only one that has figured out how valuable YouTube can be… Tai Lopez, Patrick Bet David, Gary Vee, Stefan James, Grant Cardone… There’s about 10 people in the entrepreneur space who’ve gone all-in on YouTube, and their businesses have skyrocketed as a result. So what’s really involved… How can you build up a massive audience on YouTube, and what kind of commitment does it really take? Well today Dan’s going to walk us through his entire evolution as an entrepreneur, and how he’s grown his brand to a multiple 8-figure business using YouTube as his foundation in a way that he’s never shared in any other interview before. Resources: Dan Lok on YouTube Instagram | Facebook | Twitter Superwoman on YouTube Music: Music by: RMCM & James Roche Song: Diamonds Licensed under a Creative Commons License

Dr Carolyn Lam:                Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore.                                                 Ticagrelor has shown superior efficacy to clopidogrel in the management of acute coronary syndromes. But what about in patients undergoing PCI for stable coronary artery disease? Well, our feature paper this week gives us answers to this question but you're going to have to wait to the feature discussion to hear these answers. That's coming up right after these summaries.                                                 Our first original paper this week shows that RBM20 mutation carriers have an increased risk of arrhythmias. You may recognize RBM20 as that splicing factor which targets multiple pivotal cardiac genes such as Titin and Calcium/Calmodulin-Dependent Kinase 2 Delta or CAMK2D. In today's paper first author Dr van den Hoogenhof and co-corresponding authors Dr Pinto and Creemers from Academic Medical Center Amsterdam, compared the clinical characteristics of RBM20 and Titin mutation carriers and used RBM20 knock out mice to investigate the downstream effects of RBM20 dependent splicing. They showed that loss of RBM20 disturbed calcium handling and led to more pro-arrhythmic calcium releases from the sarcoplasmic reticulum. Patients that carried a pathogenic RBM20 mutation had more ventricular arrhythmias despite a similarly depressed left ventricular function compared to patients with a Titin mutation.                                                 Targets of RBM20 splicing were enriched for calcium and ion handling genes, most notably CAMK2D and type 2 Ryanodine receptor. Loss of RMB20 induced an increased L-Type Calcium current density, intracellular calcium overload, increased sarcoplasmic reticulum calcium content and increased spontaneous calcium releases which all could be attenuated with treatment with an L-type calcium channel blocker. Furthermore, these results suggest that RBM20 mutation carriers should be closely monitored for potential electrical disturbances and cardiac arrhythmias even in the early stages of disease.                                                 Echocardiographic quantitation of degenerated mitral regurgitation is recommended in clinical guidelines but is it really scalable to routine clinical practice? First author Antoine, corresponding author Sorano from Mayo Clinic Rochester Minnesota and their colleagues looked at more than 3900 patients diagnosed with isolated mitral valve prolapse between 2003 and 2011 and to any degree of mitral regurgitation quantified by any physician or sonographer in routine clinical practice. They found that in multi-variable analysis routinely measured effective regurgitant orifice area was associated with mortality independent of left ventricular ejection fraction and systolic diameter symptoms or age and comorbidities. Furthermore, compared with general population mortality excess mortality appeared for moderate mitral regurgitation with an effective regurgitant orifice area above 20 squared millimeters and became notable with an effective regurgitant orifice area above 30 squared millimeters which then steadily increased with even higher levels of above 40. Thus, quantitation of degenerative mitral regurgitation is scalable to routine clinical practice with strong independent prognostic power when performed routinely by multiple practitioners.                                                 The next study identifies a novel mechanism of lipid homeostasis that is linked to a pseudo gene associated with the recently discovered apolipoprotein known as APOO. Co-first authors Montasser and O'Hare, corresponding author Dr Mitchell from University of Maryland School of Medicine in Baltimore, performed an array based association analysis in more than 1100 Amish subjects and identified a variant strongly associated with LDL cholesterol levels. They identified a founder haplotype on chromosome 5 which was associated with a 15 mg/dl increase in LDL cholesterol after recombination mapping, the associated region contained eight candidate genes. Using a zebra fish model to evaluate the relevance of these genes to cholesterol metabolism they found that the expression of the transcribed pseudo gene APOOP1 increased LDL cholesterol and vascular plaque formation. Thus, based on these data the authors proposed that APOOP1  regulates levels of LDL cholesterol in humans and represents a novel mechanism of lipid homeostasis.                                                 The Orion-1 trial demonstrated that inclisiran which is a small interfering RNA therapeutic that targets PCSK9 MRNA with [inaudible 00:05:42] produces significant LDL reduction. In today's study from Dr Ray from Imperial College London and colleagues, the authors described in detail the effect of inclisiran on prespecified secondary lipid and lipoprotein outcomes over time for up to 210 days and also described the individual variation and response in these measures. They found that a single 300 milligram dose of inclisiran  lowered non-HDL cholesterol at day 180 by 35% and a second dose at day 90 resulted in a 46% reduction at day 180. Similarly a single dose of 300 milligrams of inclisiran  reduced apolipoprotein B by 31% at day 180 and a second dose of 300 milligrams administered in day 90 reduced apolipoprotein B by 41%. Significant reductions in all atherogenic lipoproteins measured were sustained through today 210. Furthermore, every individual had a reduction of apolipoprotein B and non-HDL cholesterol at 180 days with the 300 milligram two-dose regimen of inclisiran. Thus, inhibiting the synthesis of PCSK9 through small interfering RNA may be a viable alternative to monoclonal antibodies with respect to effects on atherogenic lipoproteins and that brings us to the end of our summaries. Now for our feature discussion.                                                 Ticagrelor has superior efficacy to clopidogrel in the management of acute coronary syndrome but it has not really been assessed in patients undergoing PCI for stable coronary artery disease. For our feature paper today it's going to shed some light and help us with this question and these are the results of the STEEL-PC trial. I'm so pleased to have with me right now the corresponding author Dr Robert Storey from University of Sheffield in the UK as well as our associate editor who managed this none other than Dr Stefan James from Uppsala University. Thank you.                                                 Rob, could you tell us what is the issue you tried to address and because your study is not that simple, we're not used to thinking about these pharmacodynamic and kinetic studies so could you explain a bit of what you did? Rob Storey:                        Well it's quite a few concepts that we assessed in this study. We've got data from a number of studies showing that Ticagrelor both at doses of 90 mg twice daily and 60 mg twice daily is more reliable and superior P2Y12 inhibitor compared to clopidogrel. We've got this issue of very variable response to clopidogrel with some poor responders and some high responders and a range in between. That's fairly well established and part of this study was to get more data on the 60 mg dose of Ticagrelor in these stable CAD patients undergoing PCI and get some pilot data on clinical efficacy obviously this study was not part of clinical outcomes.                                                 But, there's another issue in terms of adenosine uptake so Ticagrelor has a relatively weak effect on adenosine uptake into red cells and other cells and this may or may not explain some of its clinical effects including some adverse effects such as dyspnea. We wanted to get a better idea of the impact of Ticagrelor at both these doses on adenosine uptake. Dr Carolyn Lam:                Could I ask ... Okay this may be naïve. I'm not an interventional cardiologist but why would you expect something different in an acute coronary syndrome compared to stable coronary artery disease? Is there an underlying hypothesis there? Rob Storey:                        Well there can be changes to their differences in platelet reactivity although those aren't particularly great and overwhelmed really by P2Y12 inhibitor like Ticagrelor which gives such reliable inhibition of the P2Y12 receptor. But, there have been a limited number of groups that have looked at adenosine uptake and so we wanted to get independent confirmation or not of whether Ticagrelor therapeutic concentrations impacting on adenosine uptake and get some ideas of whether it's affecting circulating adenosine levels. That's an important question in terms of understanding the mechanisms and actions of Ticagrelor. Dr Carolyn Lam:                Got it. Thanks for breaking it down so nicely. So what did you find? Rob Storey:                        What we found was surprisingly that we saw no impact of Ticagrelor at either dose and at any time point within a month after PCI on adenosine uptake. That is the circulating levels of adenosine and the rate at which adenosine is taken up by cells in the blood mainly red blood cells. The explanation for that really is that the therapeutic levels of Ticagrelor that you see are not sufficient to impact on adenosine uptake because it's a very weak inhibitor of the adenosine uptake pathway known as the MT1. The therapeutic levels are just not getting up to a high enough concentration to have a significant impact on that. Dr Carolyn Lam:                Stefan, you've thought a lot about this. What did you think of the findings? Stefan James:                    I think it's very interesting. Of course, the pharmacodynamic effects that you can measure by pretty simple means, the level of platelet inhibition, it should be similar in ACS and stable coronary artery disease and I think it's sort of confirming what Rob has been showing in other populations with ACS ... we have been very interested in trying to understand the additional mechanisms of action of Ticagrelor... try to understand the mortality rate without the benefit for Plato, for example. Was it only -- platelet  inhibition or were there other mechanisms? And, there is a specific Ticagrelor related side effect, dyspnea, which we would have been interested in understanding... is this a  mechanism of action? We can't really explain that.  There are other mechanisms and other effects that we have seen can also be explained by adenosine, so I thought it was very interesting and important to understand more about these mechanisms.   Dr Carolyn Lam:                Yeah. Stefan James:                    But I would like to ask you, Rob. Do you think this adenosine hypothesis now, is dead, or should we still try to explore this? Rob Storey:                        Well of course in this study what we didn't look at was the adenosine kinetics in the tissue level which is where we hypothesize the dyspnea may arise from stimulation of C5 is in the lung tissue so we're missing that piece of information. It's still conceivable that very weak levels of ENT-1 inhibition may impact from adenosine levels in the tissue. We're not seeing a strong ENT-1 inhibition sufficient to raise circulating levels or something that we can pick up on this in vitro assay.                                                 I think it still remains an open question. We've got this sort of contradictory information from drugs like cangrelor and other drugs in development like Elinogrel  where we don't see an impact on adenosine but they still may cause dyspnea.  So I think it's a very open question still. Stefan James:                    Do you think that your paper gives us additional strength to the hypothesis that the mortality benefit for ticagrelor as seen in Plato is explained by the platelet inhibition and the balance between the reduction in ... Rob Storey:                        Well I think what we see really in all these studies is that Ticagrelor is a fantastically effective PTY12 inhibitor. It gives you the best level of platelet inhibition during maintenance therapy out of all the available PTY12 inhibitors. And clearly having such more reliable PTY12 inhibition than clopidogrel could still be driving a mortality benefit in high risk patients so we can't exclude the adenosine pathway contributing to some of the clinical effects but I think this sways me a little bit more to the position of thinking this is most of the benefits through platelet inhibition. Dr Carolyn Lam:                Interesting. So you're on the cutting edge of this. What's the next step then? Rob Storey:                        Clearly we can see that very effective and reliable P2Y12 inhibition is important and leads to clinical benefits and I think we need to implement that wherever we're using P2Y12 inhibitors. We need to take that message and use a more consistent therapy rather among those with associated with variable response which doesn't seem to make sense. I think this stable PCI population, their risk has fallen. And we see that in this study, quite a number of patients report a response to clopidogrel but no stent thrombosis.                                                 That really reflects, I think improvements in stent design and implantation techniques, so the implication is that maybe aspirin alone is enough to prevent stent thrombosis with modern techniques if you get a good result but in the higher risk patients particularly the ACS patients it's likely you need much more reliable platelet inhibition and that's why Ticagrelor really provides this security. Dr Carolyn Lam:                So, Rob there is one thing you tested two doses and they seemed to be equivalent at least in antiplatelet inhibition, right? So what does this mean? Should we maybe preferentially use the lower dose from now on, is there still room for the higher dose? Could you share some insights there? Rob Storey:                        Well I think one has to be cautious in not jumping to adopt a dose just on the basis of pharmacodynamic data but clearly what we show is that the 60 mg dose of Ticagrelor offers a very reliable and consistent level of PTY12 inhibition and that's likely to be very effective in preventing stent thrombosis in combination with aspirin. We also show signals that were also shown in the Pegasus study that the 60 mg dose may be better tolerated such as with lower levels of dyspnea.                                                 So, there is the option for off label use of the lower dose of Ticagrelor in those who cannot tolerate the high dose due to dyspnea because certainly they'll have better platelet inhibition down titrating from 90 to 60 and if they were to switch to Clopidogrel. So I think our study offers some comfort in terms of that aspect. The only caveat is that you have to be careful not to use strong CYP3A inducers such as some epilepsy drugs with Ticagrelor cause that can increase the metabolism and we did have one case of high platelet reactivity with strong CYP3A inducers so using a higher dose initially I think is a good idea. The label says 90 mg for 1 year following ACS and the 6 is licensed beyond one year as a down titration predominantly.                                                 Our study certainly gives some comfort that down titrating earlier if a patient can't tolerate the 90 for whatever reason, seems to be a justifiable thing. And the other thing is the European guidelines support the use of Ticagrelor off label in elective PCI and our study certainly gives some comfort that off label use and the low risk elective PCI patients of the 60 mg dose can be justified at least from a pharmacodynamic point of view. Dr Carolyn Lam:                Well, thank you because that's exactly what our audience is loving to hear. How do these findings translate into the clinical practice - Would you have any other take home messages for the clinicians listening in? Rob Storey:                        Well I think one thing we looked at also was troponin release which is very common after PCI. We didn't see an impact of PTY12 inhibition high levels on troponin  release and I think that sort of caveat in terms of that's not going to be the best measure in terms of surrogate for efficacy in the PCI population. The other question really is, how much of the platelet inhibition and how much of the adenosine effects of Ticagrelor influence the clinical outcomes and clearly the studies sways towards the platelet inhibition very consistent high level of platelet inhibition explaining most of the benefits. Carolyn Lam:                      You've been listening to circulation on the run, don't forget to tune in again next week.  

In this episode, we hear from our friend Stefan James, from Project Life Mastery, as he talks with us about how to overcome your fears.

I've just put together the best Amazing Selling Machine bonus package for the new ASM9 worth $15,249 in value, that I want to give to you for FREE as a bonus when you join the Amazing Selling Machine through me. These Amazing Selling Machine bonuses include personal coaching with myself, Stefan James, as well as a done-for-you ecommerce website, funnel, and a lot more! Every bonus has a purpose in helping you build your own Amazon business from scratch. Everything compliments the Amazing Selling Machine training that you'll be going through. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

Welcome back to this weeks episode of the Coaches Corner with the affiliate marketing king himself, Stefan James! Stefan James from Project Life Mastery is diving into how coaches can create multiple revenue streams through affiliate marketing  (and not selling out in the process) Stefan James is an internet entrepreneur, life and business coach, philanthropist, and world traveler with an obsession for mastering every area of his life while fulfilling his potential as a human being and making a difference in the lives of others. He started Project Life Mastery in 2012 as a way to help others commit to mastering every area of their lives through self-development, including health, fitness, emotions, mindset, relationships, financial freedom, passive income, starting an online business, and spirituality. If you're a coach who's looking to create a few extra passive revenue streams through affiliate marketing then join Stefan James and Lucas Rubix inside this weeks episode of The Coaches Corner! Enjoy! Affiliate Marketing Episode Breakdown: 1:30: Who is Stefan James and what is Project Life Mastery 4:11: Get out of the dabbler mentality 6:02: How coaches can use affiliate marketing to help their clients 10:12: Content Marketing VS Paid Marketing? 13:36: Rules for Affiliate Marketing and Programs 16:26: Building Your Mindset and how to get past self doubt 22:42: What's Stefan James trying to Master now? 25:80: What's next for Stefan James and Project Life Mastery? Visit the Coaches Corner Podcast at www.lucasrubix.com/podcast for more and check out Project Life Mastery at www.projectlifemastery.com www.instagram.com/projectlifemastery And Lucas Rubix and the Coaches Corner at Instagram: www.instagram.com/lucasrubix Facebook: www.facebook.com/lucasrubix Website: www.lucasrubix.com

Stefan James is a 7-figure internet entrepreneur and the founder of Project Life Mastery. In this interview, we discuss Stefan’s journey as an entrepreneur, including how he generates a significant amount of revenue for his online business using affiliate marketing, why affiliate marketing is a great business model for anyone getting started online, how to use content marketing to build a brand, and other tips for building a lifestyle business.  For show notes and links to resources mentioned on this episode visit: www.lifestylebusinessmag.com/041 Subscribe to this podcast Leave a rating & review

Welcome to 21 questions with Stefan James! In this podcast, Stefan shares 21 of his favorite things, ranging from his favourite role model, book, movie, and day of the week, to name a few things. The inspiration for the creation of this video was because a follower of ProjectLifeMastery reached out to Stefan, and expressed that he wanted to learn more about who Stefan was, on a personal level. This is great opportunity to learn more and get an inside look at the life of the man behind ProjectLifeMastery! Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

Stefan James started out as someone that did not fit with the crowd, and was not really social. Through self-development, Stefan found himself to be a better person that was way more motivated and successful. Stefan then wen on to create a business off of it, but saw issues in scaling. He went from there to the digital space, but realized that his content fit way better in the Kindle sphere and very quickly build a six-figure business from it. Stefan realized that in order to create real wealth, he needed many streams of income, and thats just what he has done with Project Life Mastery and its ancillary businesses including his Kindle coaching and sales and his success coaching. Stefan truly has mastered the art of living. Stefan's Favorite Books: Awaken the Giant Within : How to Take Immediate Control of Your Mental, Emotional, Physical and Financial Destiny! The 4-Hour Workweek: Escape 9-5, Live Anywhere, and Join the New Rich Get Your Free Audio Book Links from Today's Show: www.projectlifemastery.com

Stefan James started out as someone that did not fit with the crowd, and was not really social. Through self-development, Stefan found himself to be a better person that was way more motivated and successful. Stefan then wen on to create a business off of it, but saw issues in scaling. He went from there to the digital space, but realized that his content fit way better in the Kindle sphere and very quickly build a six-figure business from it. Stefan realized that in order to create real wealth, he needed many streams of income, and thats just what he has done with Project Life Mastery and its ancillary businesses including his Kindle coaching and sales and his success coaching. Stefan truly has mastered the art of living. Stefan’s Favorite Books: Awaken the Giant Within : How to Take Immediate Control of Your Mental, Emotional, Physical and Financial Destiny! The 4-Hour Workweek: Escape 9-5, Live Anywhere, and Join the New Rich Get Your Free Audio Book Links from Today’s Show: www.projectlifemastery.com

Stefan James started out as someone that did not fit with the crowd, and was not really social. Through self-development, Stefan found himself to be a better person that was way more motivated and successful. Stefan then wen on to create a business off of it, but saw issues in scaling. He went from there to the digital space, but realized that his content fit way better in the Kindle sphere and very quickly build a six-figure business from it. Stefan realized that in order to create real wealth, he needed many streams of income, and thats just what he has done with Project Life Mastery and its ancillary businesses including his Kindle coaching and sales and his success coaching. Stefan truly has mastered the art of living. Stefan's Favorite Books: Awaken the Giant Within : How to Take Immediate Control of Your Mental, Emotional, Physical and Financial Destiny! The 4-Hour Workweek: Escape 9-5, Live Anywhere, and Join the New Rich Get Your Free Audio Book Links from Today's Show: www.projectlifemastery.com

Stefan James (Stefan Pylarinos) is the #1 bestselling author of several books including Life Mastery. As an entrepreneur, publisher, and high-level personal success trainer and coach, Stefan has achieved a lifestyle most authors and entrepreneurs only dream about. His company, Project Life Mastery, provides life-changing information, advice and tools for people who want to achieve […] The post 040: Overcome Perfectionism and Exercise Your Creative Genius with Stefan James appeared first on TCK Publishing.

Den som drabbas av en hjärtinfarkt får nästan alltid syrgas. Men behandlingen ges för att man trott att den är bra -- det finns ingen forskning som stöjder det, visar en ny forskningsgenomgång. Hjärtläkaren Stefan James från Akademiska sjukhuset i Uppsala kommenterar. Fotbolls-VM får uppmärksamhet inte bara för spelet utan också för vuvuzelorna som ackompanjerar varje match. Vi talar med akustikforskaren Karl Bolin från KTH om hur vi reagerar på ljudet av plasttrumpeterna. Gustaf Klarin har besökt Danderyds sjukhus, där ett kvinnligt uppfinnarnätverk ska se till att goda idéer tas tillvara. Programledare: Camilla Widebeck.

Sunday, September 2nd - European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria 1. Blood Pressure Drugs Reduce Mortality in Patients with Diabetes: The ADVANCE Study REFERENCE: Abstract 312 Hot Line 1 Sunday STEPHEN MACMAHON, The George Institute, University of Sydney COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MN The randomised placebo controlled ADVANCE study of 11000 patients with diabetes has demonstrated that a combination of the ACE inhibitor, perindopril, with the diuretic indapamide can lower blood pressure and mortality. The investigators saw an impact even in patients who did not have high blood pressure. Lead study author Stephen MacMahon said this approach should be included in current practise guidelines. Sarah Maxwell spoke with him at the meeting in Vienna. Commented on Stephen McMahon's presentation of the ADVANCE study looking at the use of perindopril plus indapamide among patients with diabetes: a study with 11 000 patients divided between active and placebo in which a 14 per cent improvement in all-cause mortality, an 18 per cent reduction of cardiovascular deaths, was achieved together with reductions of the incidence of both renal and coronary disease. 2. Lifestyle and Heart Disease in Europe: A Growing Problem REFERENCE: Abstract 316 DAVID WOOD, Charing Cross Hospital, London Among 8000 coronary patients in 9 European countries, smoking prevalence hasn’t changed over the last 12 years, and obesity is going up – that’s according to the combined EUROASPIRE surveys, which were presented at the ESC congress. Derek Thorne got more from David Wood, of Charing Cross Hospital in London. 3. Drug Eluting Stents, Bare Metal Stents: No Survival Difference REFERENCE: Hot Line 1 Sunday 11:00 2 Sept/ESC Congress 2007 Vienna 1-5 September STEFAN JAMES, Uppsala Clinical Research Centre, Sweden COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MN Another year’s results of the long term outcome of using drug-eluting stents as compared with bare-metal stents from Sweden reveal that there is no longer an increased risk of late mortality when using drug-eluting stents according to Stefan James of Uppsala Clinical Research Centre. He suggested that improvements in technique have helped reduce the risk of death or myocardial infarction associated with using drug-eluting stents nevertheless the risk of blood clots still remains. Overall survival of patients was found to be the similar for both categories of stent.